Literature DB >> 27869207

Erratum: Control of ADAM17 activity by regulation of its cellular localisation.

Inken Lorenzen, Juliane Lokau, Yvonne Korpys, Mirja Oldefest, Charlotte M Flynn, Ulrike Künzel, Christoph Garbers, Matthew Freeman, Joachim Grötzinger, Stefan Düsterhöft.   

Abstract

Entities:  

Year:  2016        PMID： 27869207      PMCID： PMC5116779          DOI： 10.1038/srep37364

Source DB:  PubMed          Journal:  Sci Rep        ISSN： 2045-2322            Impact factor:   4.379


× No keyword cloud information.
. This Article contains an error in panel B of Figure 4, where the 60 minute PMA stimulation results for ‘DN-AP180’ cannot be clearly seen. The correct Figure 4 appears below as Figure 1.
Figure 1
  2 in total

1.  Novel Therapeutic Anti-ADAM17 Antibody A9(B8) Enhances EGFR-TKI-Mediated Anticancer Activity in NSCLC.

Authors:  Zheng Yang; Kin Iong Chan; Hang Fai Kwok; Kin Yip Tam
Journal:  Transl Oncol       Date:  2019-08-23       Impact factor: 4.243

2.  The metalloproteinase ADAM10 requires its activity to sustain surface expression.

Authors:  Anke Seifert; Stefan Düsterhöft; Justyna Wozniak; Chek Z Koo; Michael G Tomlinson; Elisa Nuti; Armando Rossello; Doretta Cuffaro; Daniela Yildiz; Andreas Ludwig
Journal:  Cell Mol Life Sci       Date:  2020-05-05       Impact factor: 9.261
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.